SpaceX Launches Private Astronauts on First Crewed Polar Orbit
AFP | Cape Canaveral, United States
Email :
SpaceX launched the first human spaceflight directly over Earth's polar regions on Monday—a privately funded, days-long orbital mission involving four astronauts.
Named 'Fram2' after the famed Norwegian ship built in the 19th century for Arctic and Antarctic expeditions, the mission will feature a range of experiments, including taking the first X-ray in space and growing mushrooms in microgravity.
It's hoped that the research will support future long-duration space travel to Mars.
The crew launched aboard a SpaceX Crew Dragon capsule on a Falcon 9 rocket at 9:46 p.m. Monday (0146 GMT Tuesday) from NASA's Kennedy Space Center in Florida.
Cheers rang out in the control room as the powerful rocket roared upward, lighting up the night sky with a long, orange plume of flame as the craft began its journey toward Earth's North and South Poles.
'With the same pioneering spirit as early polar explorers, we aim to bring back new data and knowledge to advance the long-term goals of space exploration,' mission commander Chun Wang said before the launch.
Wang, a Chinese-born Maltese adventurer and co-founder of crypto companies f2pool and skatefish, selected the rest of the crew:
The team trained for eight months in preparation for the approximately four-day trip, including a wilderness expedition in Alaska to simulate living in close quarters under harsh conditions.
Upon returning to Earth, the crew will attempt to exit the spacecraft without additional medical support—part of a study to help researchers understand how well astronauts can perform basic tasks after spaceflight.
Except for the Apollo lunar missions, Earth's polar regions have remained out of view for astronauts, including those aboard the International Space Station (ISS). Even on Apollo, they did not fly directly over the Earth's poles.
SpaceX has carried out five private astronaut missions to date—three in collaboration with Axiom Space to the ISS and two free-flying in Earth orbit.
The first of these was Inspiration4 in 2021, followed by Polaris Dawn, which featured the first spacewalk conducted by private astronauts.
Both free-flying missions were chartered by e-payments billionaire Jared Isaacman, who has also been nominated by President Donald Trump to serve as the next NASA administrator.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Tribune
4 days ago
- Daily Tribune
Scientists Crack Mystery Behind Planet-Shaking Nine-Day Tremors
A year after the Earth mysteriously trembled every 90 seconds for nine days straight—twice—scientists have finally traced the cause of the bizarre global seismic activity. The long-standing mystery has now been put to rest, thanks to a breakthrough study using cutting-edge satellite technology. In September 2023, seismometers around the world picked up rhythmic tremors occurring at regular 90-second intervals. The unexplained shaking lasted for nine days and reoccurred just a month later. These anomalies defied all known tectonic behavior and left scientists around the globe searching for answers. Now, in a study published in Nature Communications, researchers led by Thomas Monahan, a Schmidt AI in Science Fellow at the University of Oxford, have confirmed that the unusual seismic signals were caused by two colossal landslides in East Greenland's remote Dickson Fjord. These massive collapses triggered equally massive "mega-tsunamis," which in turn produced a phenomenon known as seiches—enormous standing waves that repeatedly sloshed within the fjord, creating rhythmic pulses that shook the Earth's crust. 'Previous studies in 2024 proposed the landslide-tsunami theory based on seismic patterns, but we lacked direct evidence to conclusively prove the link,' said Monahan. 'Our research now confirms it.' The key breakthrough came from data collected by NASA's Surface Water and Ocean Topography (SWOT) satellite, launched in December 2022. Using a unique radar altimetry technique, SWOT is capable of mapping water levels across 90% of Earth's surface in stunning detail. While traditional satellites missed the phenomenon due to infrequent measurements and complex fjord topography, SWOT's high-resolution twin-antenna system succeeded where others failed. The satellite captured the dynamic surface changes in the fjord as the seiches surged back and forth, providing the first-ever direct observations of the event and allowing researchers to match them precisely with the seismic data. 'This is a prime example of how new technology can transform our understanding of natural phenomena,' Monahan noted. The findings not only close a major scientific mystery but also open new pathways for monitoring remote and rugged environments using advanced satellite systems. As Earth's climate continues to shift, such insights could prove vital in understanding and anticipating the impacts of sudden geological events.
Daily Tribune
4 days ago
- Daily Tribune
Huge planet discovered orbiting tiny star puzzles scientists
AFP | Paris Astronomers announced yesterday they have discovered a massive planet orbiting a tiny star, a bizarre pairing that has stumped scientists. Most of the stars across the Milky Way are small red dwarfs like TOI-6894, which has only 20 percent the mass of our Sun. It had not been thought possible that such puny, weak stars could provide the conditions needed to form and host huge planets. But an international team of astronomers have detected the unmistakable signature of a gas giant planet orbiting the undersized TOI-6894, according to a study in the journal Nature Astronomy. This makes the star the smallest star yet known to host a gas giant. The planet has a slightly larger radius than Saturn, but only half its mass. It orbits its star in a little over three days. The astronomers discovered the planet when searching through more than 91,000 low-mass red dwarfs observed by NASA's TESS space telescope. Its existence was then confirmed by ground-based telescopes, including Chile's Very Large Telescope. 'The fact that this star hosts a giant planet has big implications for the total number of giant planets we estimate exist in our galaxy,' study co-author Daniel Bayliss of the UK's Warwick University said in a statement. Another co-author, Vincent Van Eylen, of University College London, said it was an 'intriguing discovery'. 'We don't really understand how a star with so little mass can form such a massive planet!' he said. 'This is one of the goals of the search for more exoplanets. By finding planetary systems different from our solar system, we can test our models and better understand how our own solar system formed.'
Daily Tribune
5 days ago
- Daily Tribune
New hope for patients with less common breast cancer
A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported Monday. Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new firstline therapy for people with HER2-positive metastatic breast cancer -- the advanced stage of a form that comprises 15–20% of all breast cancer cases. HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. 'Seeing such a striking improvement was really impressive to us -- we were taking a standard and almost doubling how long patients could have their cancer controlled for,' oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP. The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug. 'Smart bomb' This 'smart bomb' strategy allows the drug to target cancer cells directly. 'You can bind to the cancer cell and dump all that chemo right into the cancer cells,' explained Tolaney. 'Some people call them smart bombs because they're delivering chemo in a targeted fashion -- which is how I think we're able to really increase efficacy so much.' Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring. T-DXd is already approved as a 'second-line' option -- used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab. In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects. A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled -- but those results haven't yet been reported. 44 percent risk reduction At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44% compared to standard care. Fifteen percent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5% in the THP group. Because this was an interim analysis, the median progression-free survival -- meaning the point at which half the patients had seen their cancer return or worsen -- was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in. Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimizing how long patients remain on the treatment, particularly those showing complete remission. 'This represents a new firstline standard treatment option for HER2-positive metastatic breast cancer,' said Dr. Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study.
